<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929512</url>
  </required_header>
  <id_info>
    <org_study_id>HM-MERO-103</org_study_id>
    <nct_id>NCT01929512</nct_id>
  </id_info>
  <brief_title>Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mg</brief_title>
  <official_title>An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 750/20 mg and Coadministration of Metformin SR 750 mg and Rosuvastatin 20 mg in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetic characteristics between HCP1201 tablet 750/20 mg and
      co-administration of metformin 750 mg plus rosuvastatin 20 mg under fasted and fed state,
      respectively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After
      the Administration of HCP1201 Tablet 750/20 mg and Coadministration of Metformin SR 750 mg
      and Rosuvastatin 20 mg in Healthy Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>metformin, rosuvastatin Cmax</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>metformin, rosuvastatin AUClast</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin Tmax</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin T1/2</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin AUCinf</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin CL/F</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin Vd/F</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>HCP1201, Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single oral dose of the HCP1201 750/20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin and Rosuvastatin, Part1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCP1201, Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single oral dose of the HCP1201 750/20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin and Rosuvastatin, Part 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1201 750/20mg</intervention_name>
    <description>750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.</description>
    <arm_group_label>HCP1201, Part 1</arm_group_label>
    <arm_group_label>HCP1201, Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin SR 750mg</intervention_name>
    <description>Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.</description>
    <arm_group_label>Metformin and Rosuvastatin, Part1</arm_group_label>
    <arm_group_label>Metformin and Rosuvastatin, Part 2</arm_group_label>
    <other_name>Glucophage SR 750 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <description>Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.</description>
    <arm_group_label>Metformin and Rosuvastatin, Part1</arm_group_label>
    <arm_group_label>Metformin and Rosuvastatin, Part 2</arm_group_label>
    <other_name>Crestor 20mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteer, age 20~55 years

          2. The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 27 kg/m2

          3. Subject who has the ability to comprehend the study objectives, contents and the
             property of the study drug before participating in the trial

          4. Subject who has the ability and willingness to participate the whole period of trial

        Exclusion Criteria:

          1. Presence of medical history or a concurrent disease that may interfere with treatment
             and safety assessment or completion of this clinical study, including clinically
             significant disorders in kidney, liver, cardiovascular system, respiratory system,
             endocrine system, or neuropsychiatric system.

          2. Glomerular filtration rate is under 60ml/min which is calculated by serum creatinine
             value.

          3. Liver enzyme (AST, ALT) level exceeds the maximum normal range more than one and a
             half times.

          4. SBP: lower than 90mmHg or higher than 150mmHg, DBP: lower than 60mmHg or higher than
             100mmHg

          5. History of relevant drug allergies or clinically significant hypersensitivity
             reaction.

          6. History of drug abuse or positive drug screening.

          7. Participation in other drug studies within 60days prior to the drug administration.

          8. Whole blood donation within 60 days, blood component donation within 30 days or who
             got transfusion within 30days.

          9. Subjects who took prescription drugs within 14 days from the patient screening or
             non-prescription medicine within 7 days which can affect the result of this clinical
             trial (acceptable according to the investigator's judgement)

         10. Subjects who took medicines(e.g. proton pump inhibitor, rifampicin, oriental
             medicines, etc.) within 30days that can affect absorption, distribution, metabolism,
             elimination of metformin/rosuvastatin.

         11. Intake of more than 140g of alcohol per week or who can't abstain from alcohol during
             the trial.

         12. Subjects who smoke more than 10 cigarettes per day or who can't quit smoking during
             the trial.

         13. Positive screening on Hepatitis B surface antigen(HBsAg), anti-Hepatitis C virus(HCV)
             or anti-Human immunodeficiency virus(HIV).

         14. Genetic myopathic disorder or related family history, medical history of myopathic
             disorder caused by medication.

         15. Clinically inappropriate laboratory test result.

         16. Clinically inappropriate electrocardiogram result.

         17. Subjects who judged ineligible by the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JaeWook Ko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

